Search Results
Found 3 results
510(k) Data Aggregation
(258 days)
MLX - Medial Lateral Expandable Lumbar Interbody System
The NuVasive® MLX™ - Medial Lateral Expandable Lumbar Interbody System is indicated for intervertebral body fusion of the spine in skeletally mature patients. The System is designed for use with autogenous bone graft to facilitate fusion. The MLX – Medial Lateral Expandable Lumbar Interbody System is intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the MLX - Medial Lateral Expandable Lumbar Interbody System. The MLX -Medial Lateral Expandable Lumbar Interbody System is intended to be used with supplemental internal spinal fixation systems that are cleared by the FDA for use in the lumbar spine.
The NuVasive MLX – Medial Lateral Expandable Lumbar Interbody System is manufactured from Ti-6Al-4V ELI conforming to ASTM F136 and ISO 5832-3, Ti-6Al-4V conforming to ASTM 1472, and Nitinol SE508 conforming to ASTM F2063. The implants are available in a variety of different shapes and sizes to suit the individual pathology and anatomical conditions of the patient. This 510(k) covers design changes to MLX - Medial Lateral Expandable Lumbar Interbody System (K140770).
This document is a 510(k) premarket notification for a medical device, the NuVasive® MLX™-Medial Lateral Expandable Lumbar Interbody System. It details the device's indications for use, technological characteristics, and performance data to demonstrate substantial equivalence to previously cleared predicate devices.
Here's an analysis based on your request:
1. Table of Acceptance Criteria and Reported Device Performance
Acceptance Criteria | Reported Device Performance |
---|---|
Mechanical Performance (demonstrated through nonclinical testing): | The subject device exhibited performance comparable to the predicate devices in the following tests: |
Dynamic axial compression per ASTM F2077 | Met: Testing was performed per ASTM F2077. (Specific numerical results are not provided in this summary, but the conclusion states "the subject NuVasive MLX – Medial Lateral Expandable Lumbar Interbody System has been shown to be substantially equivalent to legally marketed predicate devices.") |
Dynamic torsion per ASTM F2077 | Met: Testing was performed per ASTM F2077. (Specific numerical results are not provided.) |
Static push-out per ASTM Draft Standard F-04.25.02.02 (work item Z8423Z) | Met: Testing was performed per ASTM Draft Standard F-04.25.02.02. (Specific numerical results are not provided.) |
Structural Integrity (demonstrated through Finite Element Analysis and engineering rationale): | The modified design does not create a new worst-case scenario for performance. |
Equivalent or improved structural integrity compared to predicate devices with design modifications | Met: Finite Element Analysis (FEA) and engineering rationale were provided as evidence that the modified design does not create a new worst case for performance testing. (Specific FEA results or comparisons are not provided in this summary.) |
Material Composition (demonstrated through material standards compliance): | Materials used conform to established standards. |
Ti-6Al-4V ELI conforming to ASTM F136 and ISO 5832-3 | Met: Manufactured from Ti-6Al-4V ELI conforming to ASTM F136 and ISO 5832-3. |
Ti-6Al-4V conforming to ASTM F1472 | Met: Manufactured from Ti-6Al-4V conforming to ASTM F1472. |
Nitinol SE508 conforming to ASTM F2063 | Met: Manufactured from Nitinol SE508 conforming to ASTM F2063. |
2. Sample Size Used for the Test Set and Data Provenance
The document only describes nonclinical testing and Finite Element Analysis (FEA) for the device. Clinical data (human subject testing) for a "test set" in the context of device performance in patients (e.g., efficacy, safety) is not mentioned in this 510(k) summary. The testing described is pre-market, bench-top lab testing for mechanical properties and computational analysis.
Therefore, the concepts of "sample size for the test set" and "data provenance (country of origin, retrospective/prospective)" as they relate to human patient data are not applicable to the data presented in this particular 510(k) summary.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and their Qualifications
This information is not applicable as the data presented is from nonclinical (bench and computational) testing, not clinical studies requiring expert ground truth for patient outcomes. The "ground truth" here would be the established ASTM standards and engineering principles for mechanical testing and FEA. Product engineers and test lab personnel with relevant expertise would interpret these results.
4. Adjudication Method for the Test Set
This is not applicable as the document describes nonclinical mechanical and computational testing, not clinical studies that typically involve adjudication of patient outcomes or diagnostic interpretations.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, and its effect size.
This is not applicable. This 510(k) pertains to a physical medical implant (intervertebral body fusion device), not an AI/software device that would typically undergo MRMC studies for diagnostic accuracy or physician assistance.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done.
This is not applicable. The device is a physical implant, not a software algorithm.
7. The Type of Ground Truth Used
For the nonclinical performance data, the "ground truth" is based on:
- Established ASTM standards (e.g., F2077, F2063, F136, F1472) for material properties and mechanical testing.
- Engineering principles and Finite Element Analysis (FEA) models for assessing structural integrity and predicting performance under various loads.
8. The Sample Size for the Training Set
This is not applicable. There is no mention of a "training set" in the context of machine learning or AI. The testing described focuses on evaluating the physical properties and performance of the manufactured device and its design changes.
9. How the Ground Truth for the Training Set was Established
This is not applicable for the reasons stated in point 8.
Ask a specific question about this device
(76 days)
NuVasive MLX-Medial Lateral Expandable Lumbar Interbody System, NuVasive AP Expandable XLIF System
The NuVasive® AP Expandable XLIF System is indicated for intervertebral body fusion of the spine in skeletally mature patients. The system is designed for use with autogenous bone graft to facilitate fusion. The AP Expandable XLIF System is intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the AP Expandable XLIF System. The AP Expandable XLIF System is intended to be used with supplemental internal spinal fixation systems (e.g., pedicle screw/ rod systems) that are cleared by the FDA for use in the lumbar spine.
The NuVasive® MLX™ - Medial Lateral Expandable Lumbar Interbody System is indicated for intervertebral body fusion of the spine in skeletally mature patients. The System is designed for use with autogenous bone graft to facilitate fusion. The MLX – Medial Lateral Expandable Lumbar Interbody System is intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the MLX - Medial Lateral Expandable Lumbar Interbody System. The MLX -Medial Lateral Expandable Lumbar Interbody System is intended to be used with supplemental internal spinal fixation systems that are cleared by the FDA for use in the lumbar spine.
The NuVasive Sterile MLX and APX Interbody Devices are manufactured from Ti-6Al-4V ELI conforming to ASTM F136 and ISO 5832-3, Ti-6AI-4V conforming to ASTM 1472, Nitinol SE508 conforming to ASTM F2063, and Nickel-Cobalt-Chromium-Molybdenum alloy (MP35N) conforming to ASTM F562. The implants are available in a variety of different shapes and sizes to suit the individual pathology and anatomical conditions of the patient. This 510(k) covers addition of sterile packaged implants to previously cleared systems.
This document is about the FDA 510(k) clearance of the NuVasive® MLX™ - Medial Lateral Expandable Lumbar Interbody System and NuVasive® AP Expandable XLIF System. It does not describe an AI medical device or a study proving its performance. Thus, I cannot provide the requested information.
Ask a specific question about this device
(120 days)
MLX - MEDIAL LATERAL EXPANDABLE LUMBAR INTERBODY SYSTEM
The NuVasive MLX™ - Medial Lateral Expandable Lumbar Interbody System is indicated for intervertebral body fusion of the spine in skeletally mature patients. The system is designed for use with autogenous bone graft to facilitate fusion.
The NuVasive MLX - Medial Lateral Expandable Lumbar Interbody System is intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the NuVasive MLX - Medial Lateral Expandable Lumbar Interbody System. The NuVasive MLX - Medial Lateral Expandable Lumbar Interbody System is intended to be used with supplemental internal spinal fixation systems that are cleared by the FDA for use in the lumbar spine.
The NuVasive MLX – Medial Lateral Expandable Lumbar Interbody System is manufactured from Ti-6AI-4V ELI conforming to ASTM F136 and ISO 5832-3, Ti-6A1-4V conforming to ASTM 1472, Nitinol SE508 conforming to ASTM F2063, and Nickel-Cobalt-Chromium-Molybdenum alloy (MP35N) conforming to ASTM F562. The implants are available in a variety of different shapes and sizes to suit the individual pathology and anatomical conditions of the patient. This 510(k) covers design changes to NuVasive® Expandable Lumbar Interbody System (K130820).
The NuVasive MLX™ - Medial Lateral Expandable Lumbar Interbody System, as described in the provided 510(k) summary, is a medical device for intervertebral body fusion. The submission does not detail specific acceptance criteria or an analytical study with defined performance metrics in the way one might expect for a diagnostic or AI-driven device.
Instead, the submission focuses on demonstrating substantial equivalence to previously cleared predicate devices. This means the primary "acceptance criteria" were met by proving that the modified design of the MLX System device does not introduce new worst-case performance scenarios compared to the established predicates.
Here's an breakdown based on the provided document:
1. Table of Acceptance Criteria and Reported Device Performance
Acceptance Criteria (Implied) | Reported Device Performance |
---|---|
Maintain or improve mechanical performance compared to predicate devices, without introducing new worst-case scenarios. | Modifications to the MLX System were shown not to create new worst-case scenarios for performance. |
Substantial equivalence in design, intended use, material composition, and function to predicate devices. | The subject device was found to be substantially equivalent to predicates in these areas. |
Biocompatibility of materials. | Materials (Ti-6AI-4V ELI, Ti-6A1-4V, Nitinol SE508, Nickel-Cobalt-Chromium-Molybdenum alloy) conform to ASTM and ISO standards. |
2. Sample Size Used for the Test Set and Data Provenance
This information is not provided in the document. The performance data section refers to "Finite Element Analysis (FEA), anterior shear impact testing, torsional separation testing and engineering rationale." These are typically engineering tests performed on a limited number of physical samples or computational models, not a "test set" of patient data as might be relevant for AI or diagnostic devices. There is no mention of data provenance (e.g., country of origin, retrospective/prospective).
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts
This information is not applicable/not provided. For a device like the NuVasive MLX, ground truth is typically established through engineering standards, mechanical testing, and regulatory requirements, not through expert review of a "test set" in the context of diagnostic or AI performance.
4. Adjudication Method for the Test Set
This information is not applicable/not provided. Adjudication methods (like 2+1, 3+1) are common in studies involving subjective expert review (e.g., for image interpretation). For a mechanical device, performance is typically assessed against quantifiable engineering specifications.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, and the effect size of how much human readers improve with AI vs without AI assistance
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted or mentioned. This type of study is relevant for diagnostic devices, particularly those involving image interpretation with or without AI assistance, which is not the nature of the NuVasive MLX device.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done
This information is not applicable/not provided. The NuVasive MLX is a physical implantable device, not an algorithm or software. Therefore, the concept of "standalone algorithm performance" does not apply.
7. The Type of Ground Truth Used
The ground truth used for this device's "performance" is based on engineering standards, mechanical testing results, and regulatory requirements (substantial equivalence). This includes:
- ASTM and ISO standards for material composition.
- Results from Finite Element Analysis (FEA).
- Results from anterior shear impact testing.
- Results from torsional separation testing.
- Engineering rationale to demonstrate no new worst-case scenarios.
8. The Sample Size for the Training Set
This information is not applicable/not provided. The concept of a "training set" is relevant for machine learning algorithms. The NuVasive MLX is a physical medical device, not an AI or software product that undergoes "training."
9. How the Ground Truth for the Training Set Was Established
This information is not applicable/not provided for the same reason as point 8.
Ask a specific question about this device
Page 1 of 1